title: Dose-dependent inhibition of myointimal hyperplasia by orally administered rapamycin.
abstract: Myointimal hyperplasia (MIH) after vascular intervention is a major problem. Recent reports describing elimination of within-stent restenosis by means of rapamycin-eluting stents prompted us to examine the effect of systemic oral rapamycin on MIH induced by arterial trauma. We studied the effect of oral rapamycin on MIH after rabbit aorta balloon injury. Thirty-five New Zealand white rabbits (2.5-3 kg) had aortic injury and were given either no rapamycin (control), 0.1 (low dose) rapamycin mg/kg/day, or 0.4 mg/kg/day (high dose). Rapamycin was started 1 week before injury and continued for 3 (4 weeks total) or 6 weeks (7 weeks total) post-injury. Sections were analyzed to measure aortic intima/media area ratios (I:M) at either 3 or 6 weeks. At 3 weeks, the I:M (mean +/- SD) for controls was 0.53 +/- 0.1; for low dose, 0.17 +/- 0.13; and for high dose, 0.24 +/- 0.07 (p < 0.001 vs. control). At 6 weeks, the I:M for controls was 0.52 +/- 0.12; for low dose-4 weeks, 0.29 +/- 0.15; low dose-7 weeks, 0.33 +/- 0.07; and high dose-4 weeks, 0.47 +/- 0.16. At 6 weeks only the difference between the low dose-4 weeks and control I:M ratios was significant (p = 0.018). The results confirm earlier studies showing that systemic rapamycin inhibits MIH after arterial injury when drug therapy is started before injury. Therapy for 3 or 6 weeks after injury yields similar inhibition, indicating that exposure to the drug early in the response to injury is more important than prolonged exposure. We observed a paradoxical relation between dose and degree of MIH inhibition, with the low dose being more effective than the high dose at both time intervals studied. Overall, the results suggest that oral rapamycin therapy might be a useful adjunct to clinical interventions at risk for development of MIH.
authors.affiliation: Department of Surgery, University of California Irvine Medical Center, Orange 92868, USA.
authors.forename: Norio
authors.initials: N
authors.lastname: Uchimura
authors.forename: Ganesha B
authors.initials: GB
authors.lastname: Perera
authors.forename: Roy M
authors.initials: RM
authors.lastname: Fujitani
authors.forename: Jonathan M
authors.initials: JM
authors.lastname: Tobis
authors.forename: Shin
authors.initials: S
authors.lastname: Ishimaru
authors.forename: Samuel E
authors.initials: SE
authors.lastname: Wilson
authors.forename: Ian L
authors.initials: IL
authors.lastname: Gordon
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D001011:Aorta / Q000187:drug effects / Q000293:injuries; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000187:drug effects / Q000293:injuries; D006965:Hyperplasia / Q000188:drug therapy; D008955:Models, Cardiovascular; D011817:Rabbits; D020123:Sirolimus / Q000008:administration & dosage*; D013997:Time Factors; D017539:Tunica Intima / Q000187:drug effects* / Q000473:pathology*
chemical_list: D000903:Antibiotics, Antineoplastic; D020123:Sirolimus